Current Hematologic Malignancy Reports

, Volume 1, Issue 1, pp 51-59

First online:

First-line treatment of Hodgkin’s lymphoma

  • Beate KlimmAffiliated withFirst Department of Internal Medicine, University Hospital Cologne Email author 
  • , Andreas Engert
  • , Volker Diehl

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Substantial clinical progress over the last decades has made Hodgkin’s lymphoma into one of the most curable human cancers in adults. About 80% of patients in all stages and of all histologic subtypes experience long-term disease-free survival. Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related toxicities. Ongoing trials investigate a reduction of chemotherapy doses or cycles and the application of lower radiation doses and smaller radiation field sizes. For patients with a specific high-risk profile, novel approaches with more intense drug combinations are currently being investigated in clinical trials. This review discusses recent approaches to the first-line treatment of early-favorable, early-unfavorable, and advanced-stage Hodgkin’s lymphoma.